VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to mitigate the nephrotoxic effects associated with conventional polymyxin B (PMB) therapy Key preclinical findings for VRP-034 included up to 70% reduction in nephrotoxicity compared to marketed PMB The QIDP